Andy Oh

Andy Oh is the CFO of Serif and brings three decades of expe­ri­ence in finance and the bio­phar­ma­ceu­ti­cal indus­try. Pri­or to Serif, Andy was a Senior Part­ner at Flag­ship Pio­neer­ing for sev­er­al years where he led cap­i­tal for­ma­tion efforts for the firm’s NewCos.

Before Flag­ship, Andy served as CFO of Rubius Ther­a­peu­tics, a Flag­ship-found­ed com­pa­ny, where he raised $453 mil­lion in cap­i­tal, includ­ing a $277 mil­lion ini­tial pub­lic offer­ing — at the time, the high­est-val­ued pre­clin­i­cal biotech IPO in Wall Street his­to­ry. Pri­or to Rubius, Andy spent a decade as a port­fo­lio man­ag­er at Leerink and Fideli­ty, invest­ing in phar­ma­ceu­ti­cal and biotech­nol­o­gy com­pa­nies. While at Fideli­ty, he man­aged the Fideli­ty Select Phar­ma­ceu­ti­cals Port­fo­lio for sev­en years, dur­ing which it was rat­ed by Lip­per as the top glob­al health fund based on his three- and five-year per­for­mance. Under his lead­er­ship, the fund grew from approx­i­mate­ly $160 mil­lion to $1 billion.

Ear­li­er in his career, Andy was a senior ana­lyst cov­er­ing glob­al phar­ma­ceu­ti­cal com­pa­nies at Leerink and was an asso­ciate on JPMorgan’s #1 Insti­tu­tion­al Investor – ranked U.S. Phar­ma­ceu­ti­cal team.

Andy holds an MBA from North­west­ern University’s Kel­logg School of Man­age­ment and a BA in biol­o­gy from Wash­ing­ton Uni­ver­si­ty in St. Louis.